切换导航
About Us
Our Story
Our Mission
History
Global Footprint
Leadership
Board of Directors
Science & Technology
Pipeline
Collaborations
CDMO Services
About CDMO
Strength
Services Offered
Learn More
Investors & Media
Join Us
EN
中文
Our RNA Encodes
Innovation
/science.html
Transforming Somatic Cells into a Drug Factory
View More
Latest news
News Update
Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development
View More
2024.08.26
News Update
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
View More
2024.07.09
News Update
Immorna Biotherapeutics Presents Clinical Data for JCXH-211, a Self-Replicating RNA Encoding the Human IL-12, at ASCO 2024
View More
2024.06.06
News Update
Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
View More
2023.05.31
View All
Diverse pipeline utilizing multiple mRNA platforms, including conventional, self-replicating and circular mRNA.
View More